

Drug discovery & Development: GAME CHANGERS

09 February 2011 | News



Research & development is the lifeblood of the biotech industry. *BioSpectrum* in this special issue has brought together some of the R&D leaders from the industry to share their thoughts on the “Game Changers in Drug Discovery & Development”.

Later this month, *BioSpectrum* is organizing the second edition of the *BioSpectrum* Technology Forum 2011 (BSTF 2011) which has a series on interactive panel discussions with the same theme: “Game Changers in Drug Discovery & Development.” This two-day forum will be held in Bangalore on February 22-23, 2011.

During these two days, senior scientists and R&D heads from public and private sectors across the country will be sharing their insights & experiences on topics such as “Stem Cells & Gene Therapy, Next Generation Innovation, Strengthening the Drug Pipeline, Computer-aided Drug Discovery, and Novel Approaches to Drug Discovery.” In the ensuing pages, read on some insights from these R&D leaders:

*(The views expressed in these articles are strictly the personal views of the author. The trademarks or trade names mentioned in this paper are property of their respective owners and are included for reference only and do not imply a connection or relationship between the author and these companies or *BioSpectrum*.)*

[Mr Venkat Jasti, chairman & CEO, Suven Life Sciences](#)

[Dr Arumugam Muruganandam, Chief Scientific Manager Research & Development Biocon](#)

[Dr Chandra Viswanathan, Head, Regenerative Medicine, Reliance Life Sciences](#)

[Dr Gopal Dasika, VP, Biotech, Unichem](#)

[Dr Samuel JK Abraham, Director, Nichi-In Centre for Regenerative Medicine](#)

[Dr Janakiraman Ramachandran, Chairman & CEO Gangagen Inc](#)

[Mr BN Manohar, CEO, Stempeutics](#)

[Mr Ganesh Sambasivam, Founder & CSO, Anthem Biosciences](#)